Controlling Out of Pocket (OOP) Expenses for Medicare Prescriptions While not directly related to CLL, this second FDA approved indication is another reason to anticipate that zanubrutinib will soon... September 27, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma While not directly related to CLL, this second FDA approved indication is another reason to anticipate that zanubrutinib will soon... September 17, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia on September 01, 2021 While not directly related to CLL, this second FDA approved indication is another reason to anticipate that zanubrutinib will soon... September 5, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Oral Parity: H.R. 4385 Could Lower Your CLL Drug Cost! Below is an appeal from Tom Henry, a pharmacist, CLL patient and longtime friend of the CLL community and the... August 27, 2021Business, Finances, Insurance & RegulatoryBy Brad Hedrick
Newsflash: FDA Authorizes Third Vaccine Dose for the Immunocompromised (8/15/21 Update) We still have work to do, but for right now, let’s celebrate this major win for CLL and other immunocompromised... August 13, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, COVID-19By Brad Hedrick
FDA Authorizes New Test Built With Machine Learning to Detect Past COVID-19 Infections Adaptive Biotech received FDA emergency use authorization for T-Detect™ COVID, its test for past COVID-19 infections using genetic techniques to... March 12, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, COVID-19, NewsBy Brad Hedrick
FDA Approves Lisocabtagene Maraleucel (liso-cel or JCAR-017) a CAR-T Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... February 6, 2021Business, Finances, Insurance & Regulatory, CAR-T, NewsBy Brad Hedrick
CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia (CLL) This was a gutsy trial, a first of its kind head-to-head comparison between two Bruton Tyrosine Kinase (BTK) inhibitors, acalabrutinib... January 29, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
COVID Patient Support Program Extension: Free Medication from Bristol Myer Squibb (BMS) Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... January 27, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, NewsBy Brad Hedrick
NCCN Recommends Zanubrutinib as First-Line and Second-Line Therapy in CLL/SLL NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL... January 4, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
